BN Business News
Bedrijf toevoegen →
Deze vertaling wordt voorbereid. Voorlopig tonen we de oorspronkelijke Engelse versie.

Bedrijven · 13-4-20221 min lezen

Secura Bio, Inc.; Withdrawal of Approval of Relapsed or Refractory Follicular Lymphoma Indication for COPIKTRA

Lokale automatische vertaling · Oorspronkelijke brontaal

Samenvatting

The Food and Drug Administration (FDA) is announcing that it is withdrawing approval of the relapsed or refractory follicular lymphoma indication for COPIKTRA (duvelisib) Capsules, approved under new drug application 211155, held by Secura Bio, Inc., 1995 Village Center Circle, Suite 128, Las Vegas, NV 89134. Secura Bio, Inc. voluntarily requested that the Agency withdraw approval of this indication and has waived its opportunity for a hearing.

Oorspronkelijke brontaal: Federal Register — Food and Drug AdministrationOrigineel bericht openen →